Junko Murai

Project Associate Professor

Keio University

Japan

Research Interests

Explore related searches

Professors in Japan Professors in Cancer Biology Cancer Biology professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Junko Murai is a Project Associate Professor at Keio University in Japan. Her research primarily focuses on the role of Schlafen 11 as a biomarker in cancer therapies, particularly in relation to platinum-based chemotherapy for various cancers including ovarian and head and neck cancers. She has published extensively on the impacts of BRCA deficiencies and synthetic lethality, as well as the epigenetic influences on cancer cell sensitivity to treatment.

Articles (13)

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Collaborators (5)

Hidehiko Akashi

Niigata University

JAPAN

View details

TAKASHI BABASAKI

Hiroshima University

JAPAN

View details

Atsuo Sasaki

Project Professor

Hiroshima University Hospital

JAPAN

View details

Yoshikazu Nagase

Osaka Medical and Pharmaceutical University

JAPAN

View details

Kazuaki Suda

Niigata University

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Junko Murai

Research Interests

Explore related searches

Contact this professor

About

Articles (13)

Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forks

Schlafen 11 (SLFN11) Kills Cancer Cells Undergoing Unscheduled Re-replication

BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality

SLFN11 is a BRCA independent biomarker for the response to platinum-based chemotherapy in high-grade serous ovarian cancer and clear cell ovarian carcinoma

Epigenetic upregulation of Schlafen11 renders WNT-and SHH-Activated medulloblastomas sensitive to cisplatin

Metabolic clogging of mannose triggers dNTP loss and genomic instability in human cancer cells

Schlafen family member 11 indicates favorable prognosis of patients with head and neck cancer following platinum-based chemoradiotherapy

The crucial role of single-stranded DNA binding in enhancing sensitivity to DNA-damaging agents for Schlafen 11 and Schlafen 13

The germline factor DDX4 contributes to the chemoresistance of small cell lung cancer cells

Reconsidering the mechanisms of action of PARP inhibitors based on clinical outcomes

Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum-based chemotherapy.

Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress.

Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression.

Collaborators (5)

Hidehiko Akashi

TAKASHI BABASAKI

Atsuo Sasaki

Yoshikazu Nagase

Kazuaki Suda

Make your next move.